Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
Efinaconazole 10% topical solution (Jublia)
The most effective topical for fungal toenail infection, on high-quality evidence. About one person in six gets a completely clear nail.
Prescription medication — not a dietary supplement
Efinaconazole is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Efinaconazole doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2013–2026 with a typical study size of 1,655 participants.
Based on 10 studies · 2 meta-analyses · 5 RCTs · 19,470 total participants
Study base
10 studies indexedBy outcome
Every outcome below: Too few graded studies.
The best-evidenced topical for this indication, and still a modest treatment in absolute terms. Cochrane rates the complete-cure result HIGH quality (RR 3.54, 95% CI 2.24-5.60), the only topical in that review to earn it, and two identically designed pivotal trials agree at 17.8% and 15.2% complete cure against 3.3% and 5.5% on vehicle. Held below Strong because roughly five patients in six do not get a clear nail, the pivotal report itself cautions that 52 weeks may be too brief to judge clinical cure, and doubling treatment to 24 months moved effective cure only 17.8% to 19.4%. Scored a point and a half above ciclopirox, whose complete-cure evidence Cochrane rates LOW.
1 trial ongoing or recruiting · 6 completed on ClinicalTrials.gov
5 of the completed trials have posted results
Registered trials show research momentum for Efinaconazole, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Efinaconazole 10% solution is a triazole antifungal painted on the nail once daily for 48 weeks. Among topical onychomycosis treatments it is the one with the strongest evidence: the 2020 Cochrane review rates its complete-cure result HIGH quality, where ciclopirox's equivalent is rated low.
It is on a nail goal for the same reason ciclopirox is, and with the same caveat: it treats an infection, and does nothing for nails that are simply brittle. What the high-quality evidence actually shows is worth stating in absolute terms rather than relative ones.
In the two pivotal trials, 17.8% and 15.2% of treated patients reached complete cure, against 3.3% and 5.5% on vehicle. That is roughly one clear nail in six, and it is the best figure any topical has produced.
Mycological cure, meaning the laboratory can no longer find the fungus, is far higher at about 55%, and the gap between those two numbers is the thing to understand before starting: killing the fungus and getting a normal-looking nail are not the same result.
The pivotal report carries its own caveat that 52 weeks may be too brief to judge clinical cure. A separate 24-month study bears that out only partly: mycological cure kept climbing, while effective cure barely moved.
Efinaconazole is a triazole. It inhibits lanosterol 14-alpha-demethylase, the enzyme fungi need to build ergosterol for their cell membranes. That is the same target the oral azoles hit, which is why it is a different pharmacological class from ciclopirox despite treating the same infection.
The design problem for every nail antifungal is that keratin binds the drug and stops it reaching the nail bed. Efinaconazole is formulated as a low-surface-tension solution with low keratin affinity, so more of the dose crosses the plate. The pivotal trials performed no debridement, so the result reflects the drug rather than mechanical nail reduction.
Consult a clinician before use. Systemic exposure from the nail is very low, but no adequate trials in pregnancy exist and onychomycosis treatment is not urgent, so deferring it is the usual course.
A pooled post-hoc analysis of 162 treated and 56 vehicle participants aged 65 and over found complete cure 13.6% against 3.6% and mycological cure 59.2% against 12.5%, broadly matching the overall trial population.
The pivotal trials enrolled adults aged 18 to 70, so the evidence summarised here does not cover children. A clinician decides.
The solution has to reach the nail bed to work, and the pivotal trials were run without cosmetic polish on the treated nail. This is a question of delivery rather than a pharmacological interaction.
The available source did not grade how severe these reactions were. This does not mean they were mild.
The available source did not grade how severe these reactions were. This does not mean they were mild.
Efinaconazole has an evidence score of 6.5/10 — moderate evidence based on 10 indexed studies, including 2 meta-analyses. The most effective topical for fungal toenail infection, on high-quality evidence. About one person in six gets a completely clear nail. Representative study: PMID 31978269.
The best time to take Efinaconazole is in the evening. It can be taken on an empty stomach. No time-of-day pharmacology.
Efinaconazole has a safety rating of "moderate". That is a category, not a measure of individual risk, and there are precautions worth knowing. Reported side effects include application-site reaction, dermatitis or vesicles, ingrown toenail. How often they occur is not established for all of them. Use caution if any of these apply to you: Known hypersensitivity to efinaconazole or any excipient of the solution.
Urea
Too few graded studiesCosmetic compoundA humectant at low strength and a keratolytic at high strength — one of the oldest, safest topicals, and rarely proven better than a cheap plain moisturiser.
Clindamycin (topical)
Too few graded studiesPrescription drugA topical antibiotic for acne that is slow rather than weak, and works best paired with a retinoid or benzoyl peroxide. Combined with a retinoid it is the most effective topical option for moderate-to-severe acne.
Dapsone (topical)
Too few graded studiesPrescription drugA topical sulfone for inflammatory acne that works measurably better in women than in men, and is safe in G6PD deficiency despite the oral drug's reputation.
Ciclopirox
Too few graded studiesPrescription drugA topical antifungal nail lacquer for fungal nail infection. It clears the fungus in roughly a third of people and leaves a normal-looking nail in far fewer.
Explore: Best supplements for Skin, Hair & Beauty
Edited by Dr. Baher Al Hakim · Last updated November 2026 · evidence from 10 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.